









Markets
/
Stocks
/
nasdaq-skye
/

Skye Bioscience Inc

SKYE

1.510USD

+0.090+6.34%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

46.79MMarket Cap

LossP/E TTM



Skye Bioscience Inc

1.510

+0.090+6.34%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Skye Bioscience Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Skye Bioscience Inc's Score

Industry at a Glance

Industry Ranking

133 / 407

Overall Ranking

266 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.714

Target Price

+513.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Skye Bioscience Inc Highlights

StrengthsRisks

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -1.42, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 20.44M shares, decreasing 31.07% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 837.96K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Skye Bioscience Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.19, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.42, which is -858.62% below the recent high of 10.76 and -263.22% above the recent low of -5.15.

Score

Industry at a Glance

Previous score

6.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 133/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Skye Bioscience Inc is 10.00, with a high of 20.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.714

Target Price

+513.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Skye Bioscience Inc

SKYE

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.95, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 1.74 and the support level at 1.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.78

Change

0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.158

Neutral

RSI(14)

36.183

Neutral

STOCH(KDJ)(9,3,3)

32.268

Neutral

ATR(14)

0.111

Low Volatility

CCI(14)

12.770

Neutral

Williams %R

42.857

Buy

TRIX(12,20)

-2.987

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.490

Buy

MA10

1.519

Sell

MA20

1.512

Sell

MA50

2.826

Sell

MA100

3.219

Sell

MA200

2.744

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 65.96%, representing a quarter-over-quarter decrease of 15.92%. The largest institutional shareholder is The Vanguard, holding a total of 837.96K shares, representing 2.70% of shares outstanding, with 2.70% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

5AM Ventures

9.68M

-2.33%

Versant Ventures

2.01M

Baker Bros. Advisors LP

1.45M

Schonfeld Strategic Advisors LLC

1.10M

-32.11%

The Vanguard Group, Inc.

Star Investors

837.96K

-12.11%

Ensign Peak Advisors, Inc.

767.29K

Driehaus Capital Management, LLC

620.39K

Sphera Funds Management Ltd.

538.43K

-63.53%

Millennium Management LLC

470.73K

Alyeska Investment Group, L.P.

456.16K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.42, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.67. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.